The Emperor of All Maladies: A History, Checked Against Where Cancer Care Actually Stands Now

The Emperor of All Maladies: A Biography of Cancer is Siddhartha Mukherjee's history of cancer, published by Scribner in November 2010. It won the Pulitzer Prize for General Nonfiction in 2011. Mukherjee is an oncologist, and the book is framed, as its subtitle suggests, as a biography of the disease itself rather than of any one patient or scientist.

It is not a memoir. Mukherjee draws on his own clinical training and his patients' cases throughout, but the organizing structure is historical and thematic: how cancer has been understood, misunderstood, and fought across roughly four thousand years, from the earliest surviving medical descriptions of tumors through the modern era of molecular biology.

The book's ambition is unusual for popular science writing about a single disease. It moves comfortably between the biography of individual researchers and physicians, the social and political history of cancer research funding in the United States, and the underlying science of what a cancer cell actually is and how it behaves differently from a normal one.

Because it is fifteen years old at the time of this page's writing, and because cancer treatment has changed substantially in that period, this page treats its early and middle chapters as history, largely still accurate as history, and treats its closing chapters, describing the treatment landscape as it stood around 2010, as dated rather than current.

The book is organized in six parts, moving roughly chronologically. It opens with ancient and early modern descriptions of cancer, including the Edwin Smith Papyrus, an Egyptian medical text describing what appears to be a case of breast cancer and the physician's note that there was no treatment.

It then moves through the era of radical surgery in the nineteenth and early twentieth centuries, the emergence of chemotherapy, including the wartime discovery that nitrogen mustard, a chemical weapon, had cancer-killing properties, and the twentieth-century American public health campaign against cancer, including the 1971 National Cancer Act and the increased federal research funding that followed, often called the war on cancer.

Later sections cover the rise of molecular biology's understanding of cancer as a genetic disease, including the discovery of oncogenes and tumor suppressor genes, and the book's closing chapters describe the earliest targeted therapies, drugs designed against a specific molecular abnormality rather than against dividing cells generally, using examples current at the time of writing.

The book is strongest as history, and specifically as an account of how much of what we now take for granted about cancer, that it is a genetic disease, that different cancers respond to different treatments, that population-wide screening and prevention efforts can meaningfully change outcomes, took decades of often wrong turns to establish.

It is also unusually good at making the human cost of scientific uncertainty visible: the chapters on early, aggressive surgical approaches, and later on high-dose chemotherapy regimens later shown to be no more effective than gentler ones, describe real harm done in good faith, before the evidence existed to know better. That honesty about medicine's mistakes, made by serious, well-intentioned people working with the information available at the time, is one of the book's most valuable qualities, and a useful frame for a reader trying to understand why cancer treatment recommendations sometimes change.

Its account of the political and funding history behind cancer research, particularly the 1971 National Cancer Act, is also a genuine contribution, explaining why the United States built the research infrastructure it currently has, including the National Cancer Institute's expanded role, in a way that connects directly to how cancer research and care are organized today.

The book's final chapters, describing the treatment landscape as of around 2010, are now the most dated part of the book by a wide margin. Immunotherapy, now a mainstay of treatment for many cancers, was in its early stages when the book was written and receives comparatively little attention. Genomic-guided treatment, now standard for many cancer types, has expanded enormously since. A reader using the book to understand current treatment options would be working from a picture that is, in places, more than a decade out of date.

Its statistics, similarly, describe cancer incidence and mortality trends as understood around 2010. Cancer death rates have continued to decline since then, and current figures should be sought from NCI directly rather than from the book's own numbers.

The book is also, by design, a history of cancer largely as understood and treated in the United States and Western medicine, and it does not cover cancer care and outcomes globally in comparable depth. A reader interested in a global picture of cancer burden and treatment access will need other sources.

It is also a long book, running past five hundred pages, and its density is deliberate rather than a flaw, but it means it is not the fastest source for a reader who wants a quick answer to a specific question. Someone newly diagnosed and looking for immediate, practical guidance about their own treatment will likely be better served starting with a source built for that purpose and returning to this book, if at all, once the immediate practical questions are handled.

The book's central scientific claim, that cancer is fundamentally a disease of gene mutation, remains accurate and is where the book holds up best. It is worth stating NCI's own current version of that claim directly, since it is the same underlying idea the book spends hundreds of pages establishing historically.

NCI states plainly that cancer is a genetic disease, caused by changes to genes that control how cells grow and divide. It identifies three broad categories of genes involved: proto-oncogenes, which can become cancer-driving oncogenes when mutated; tumor suppressor genes, whose loss removes a normal brake on cell division; and DNA repair genes, whose failure allows other mutations to accumulate. NCI also notes that these mutations arise from several sources: errors during ordinary cell division, damage from environmental exposures such as chemicals in tobacco smoke or ultraviolet light, and mutations inherited from a parent.

What has moved substantially since the book's publication is what can be done once a cancer's specific genetic changes are known. Mukherjee's book describes the earliest targeted therapies as a promising but young approach. Genomic testing of a patient's own tumor is now routine for many cancer types, directly shaping treatment choice in a way the book, written at the start of that shift, could only anticipate.

Because the book's own historical arc leads toward a statement about progress, it is worth checking that claim against current NCI data rather than the book's own figures.

NCI's current cancer statistics page states that the overall US cancer death rate has declined since the early 1990s, continuing to fall in the most recent reporting period, by roughly 1.7 percent annually for men and 1.3 percent for women. That decline reflects a combination of factors the book's later chapters gesture toward but could not fully report on at the time of writing: reduced smoking rates, expanded and improved screening, and treatment advances including many that came after 2010.

That is not a small correction to the book's narrative; it is closer to a continuation of it. The book ends on cautious, historically grounded optimism about the direction of cancer research. The subsequent fifteen years of declining mortality broadly support that optimism, even as the specific treatments the book describes as cutting-edge have since been supplemented, and in some cases superseded, by newer approaches.

It is worth being specific about what that decline does and does not mean. A falling national death rate reflects population-level trends across all cancer types combined, driven heavily by large, common cancers such as lung cancer, where reduced smoking has had an outsized effect. It does not mean every cancer type has improved equally, and it says nothing directly about any individual patient's prognosis, which depends on the specific type, stage, and biology of their disease rather than on a national average.

For a current, detailed picture of how a cancer diagnosis is actually staged and treated today, see cancer staging, targeted therapy, and, for one of the clearest single examples of that shift, The Philadelphia Chromosome.

It suits a reader who wants to understand cancer's history, and how the current landscape of research, funding, and treatment came to look the way it does, in real depth. Its combination of narrative skill and genuine scientific grounding is rare, and it remains a good introduction to cancer as a subject for a reader with no clinical background.

It is not the right source for current treatment information, current statistics, or an up-to-date picture of what a specific diagnosis means today. A reader who has just been diagnosed and wants to understand their own situation should treat this book as background and context, useful for understanding how we got here, and go to current clinical sources, including this site and NCI directly, for anything specific to their own care.

Cancer Explained is free and ad-free, and you can support this work if it helped.

• The Emperor of All Maladies — publisher's page (Simon & Schuster)
• NCI — What Is Cancer?
• NCI — Cancer Statistics
• NCI — Risk Factors for Cancer

This page discusses The Emperor of All Maladies for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care.